Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

China-Based WuXi Advanced Therapies Opens Philadelphia, Pennsylvania, Testing Facility

11/19/2021
WuXi Advanced Therapies, a wholly owned subsidiary of China-based WuXi AppTec, opened its advanced therapies testing facility at 400 Rouse Boulevard in Philadelphia, Pennsylvania.

The new state-of-the-art facility is an expansion of WuXi ATU’s existing Navy Yard Campus, which opened in 2020. This addition will strengthen the existing analytical development and testing capacity and capability.

“WuXi ATU has significant expertise in assay development, biologics safety testing, viral clearance and commercial lot release assays, and we are proud to bring that knowledge to our customers,” said Dr. David Chang, CEO of WuXi ATU. “We are committed to enabling these partners to bring ground-breaking therapeutics to patients as quickly, reliably and consistently as possible.”

The new facility, which includes 140,000 square feet laboratories, will further enhance the company’s Contract Testing, Development and Manufacturing Organization business model by tripling the company’s previous testing capacity, meeting the increasing needs of customers in the cell and gene therapy industry.

“WuXi ATU has always been at the forefront of innovation in Philadelphia,” said Kate McNamara, PIDC’s Senior Vice President, Navy Yard. “We are thrilled to celebrate their continued expansion and growth with the opening of the new advanced therapies testing facility at the Navy Yard.”

As a CTDMO with operations globally, WuXi ATU’s unique business model integrates powerful testing capabilities with its advanced therapies process development and manufacturing platforms, such as TESSA technology for AAV manufacturing and XLenti stable solutions for lentiviral manufacturing. This allows all assay development, biosafety, viral clearance and product release testing to be completed in-house, shortening customers’ timelines for the approval of advanced therapies.

Exclusive Research